Abstract:Paclitaxel has shown significant anti-tumor activity against non-small cell lung cancer (NSCLC); however, resistance to paclitaxel frequently occurs and represents a significant clinical problem and its underlying molecular mechanism remains elusive.Long-term treatment of culture cell with paclitaxel was carried out to mimic the development of acquired drug resistance in NSCLC. Cell proliferation and clonogenic assay and apoptosis evaluation were carried out to determine the efficacy of paclitaxel on NSCLC cells. Western blot analyses were performed to determine the expression and activation of proteins. Apoptosis enzyme-linked immunosorbent assay was used to quantify cytoplasmic histone-associated DNA fragments. Microarray analyses were applied to explore both mRNA and miRNA expression profiles in NSCLC cells followed by integrative analysis. qRT-PCR was carried out to verify the differentially expressed mRNAs and miRNAs.The expression of 652 genes was shown to be changed at least 2-fold in paclitaxel-resistant NSCLC (H460_TaxR) cells with 511 upregulated and 141 downregulated as compared with that in parental H460 cells. The differentially expressed genes were functionally enriched in regulating the cell proliferation, cell death, and response to endogenous stimulus, and clustered in pathways such as cancer and signaling by the G protein-coupled receptor (GPCR). Moreover, 43 miRNAs were shown to be differentially expressed in H460_TaxR cells with 15 upregulated and 28 downregulated as compared with parental H460 cells. A total of 289 pairs of miRNA-potential target gene were revealed in H460_TaxR cells by bioinformatics analysis. Furthermore, integrative analysis of miRNAs and gene expression profiles revealed that dysregulated miR-362-3p, miR-766-3p, and miR-6507-3p might confer paclitaxel resistance in NSCLC via targeting MAPT simultaneously.Our findings suggested that specific manipulation of MAPT-targeting miRNAs may be a novel strategy to overcome paclitaxel resistance in patients with NSCLC especially large-cell lung carcinoma.

Ai-lncRNA EGOT enhancing autophagy sensitizes paclitaxel cytotoxicity via upregulation of ITPR1 expression by RNA-RNA and RNA-protein interactions in human cancer

TXNDC17 Promotes Paclitaxel Resistance Via Inducing Autophagy in Ovarian Cancer

Noncoding RNAs and their therapeutics in paclitaxel chemotherapy: Mechanisms of initiation, progression, and drug sensitivity

Estrogen Receptor Α Confers Nab-paclitaxel Resistance in Breast Cancer by Promoting Mir199a-5P Maturation to Inhibit Caveolin 1 Translation

LncRNA OTUD6B-AS1 promotes paclitaxel resistance in triple negative breast cancer by regulation of miR-26a-5p/MTDH pathway-mediated autophagy and genomic instability

Inhibition of XIST Restrains Paclitaxel Resistance in Breast Cancer Cells by Targeting Hsa-Let-7d-5p/atg16l1 Through Regulation of Autophagy

IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells

Autophagy Promotes Paclitaxel Resistance of Cervical Cancer Cells: Involvement of Warburg Effect Activated Hypoxia-Induced Factor 1-Α-mediated Signaling.

Paclitaxel-resistant Related Lncrna DBH-AS1 Promotes the Proliferation and Invasion of Esophageal Cancer.

miR-141-3p promotes paclitaxel resistance by attenuating ferroptosis via the Keap1-Nrf2 signaling pathway in breast cancer

&Lt;p>integrative Gene Expression Profiling Reveals That Dysregulated Triple Micrornas Confer Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Co-Targeting MAPT</p>

Targeting Galectin-1 Overcomes Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma

A Novel miR-98 Negatively Regulates the Resistance of Endometrial Cancer Cells to Paclitaxel by Suppressing ABCC10/MRP-7

Overexpression of Microrna-24 Increases the Sensitivity to Paclitaxel in Drug-Resistant Breast Carcinoma Cell Lines Via Targeting ABCB9.

Next Generation Deep Sequencing Identified a Novel Lncrna N375709 Associated with Paclitaxel Resistance in Nasopharyngeal Carcinoma

CD147 supports paclitaxel resistance via interacting with RanBP1

Overexpression of Centrosomal Protein Nlp Confers Breast Carcinoma Resistance to Paclitaxel

Construction of a Paclitaxel-Related Competitive Endogenous RNA Network and Identification of a Potential Regulatory Axis in Pancreatic Cancer.

Silencing of PGK1 Promotes Sensitivity to Paclitaxel Treatment by Upregulating XAF1-Mediated Apoptosis in Triple-Negative Breast Cancer

Targeting lncRNA DDIT4‐AS1 Sensitizes Triple Negative Breast Cancer to Chemotherapy via Suppressing of Autophagy

The MRVI1-AS1/ATF3 signaling loop sensitizes nasopharyngeal cancer cells to paclitaxel by regulating the Hippo–TAZ pathway